PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden - Gale - 2023 - Acta Ophthalmologica - Wiley Online Library

Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence - ScienceDirect

PDF) Rate of vision loss in neovascular age-related macular degeneration explored

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

A prospective, observational, open‐label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age ‐related macular degeneration - Asten - 2015 - Acta Ophthalmologica - Wiley Online Library

Biomolecules, Free Full-Text

A prospective, observational, open‐label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age ‐related macular degeneration - Asten - 2015 - Acta Ophthalmologica - Wiley Online Library

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

PDF) Ranibizumab for the treatment of wet AMD: A summary of real-world studies